StoxLaurus Labs vs Mankind Pharma: share price & financials comparison
NSE: LAURUSLABS vs MANKIND · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Laurus Labs vs Mankind Pharma at a glance
Laurus Labs (LAURUSLABS) has a market capitalisation of ₹1,30,969 Cr, against ₹1,09,032 Cr for Mankind Pharma (MANKIND). Over the past year Laurus Labs has returned +146.6%, compared with +11.4% for Mankind Pharma. On valuation, Mankind Pharma trades at a lower P/E of 48.5 versus 97.7. Laurus Labs earns a higher return on equity (22.1% vs 12.8%). Laurus Labs comes out ahead on profitability, growth, momentum and technicals. Mankind Pharma comes out ahead on size, valuation and financial health. Across the scored metrics below, Laurus Labs leads on 10 and Mankind Pharma on 6. On StoxGud's 10-point checklist, Laurus Labs scores 8/10 and Mankind Pharma scores 7/10.
| Metric | Laurus Labs | Mankind Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹1,30,969 Cr | ₹1,09,032 Cr |
| Revenue (latest FY) | ₹6,813 Cr | ₹14,278 Cr |
| Net profit (latest FY) | ₹889 Cr | ₹1,913 Cr |
| Valuation | ||
| P/E | 97.7 | 48.5 |
| P/B | 21.61 | 6.20 |
| Dividend yield | 0.07% | 0.04% |
| Profitability | ||
| Return on equity | 22.1% | 12.8% |
| Net profit margin | 17.1% | 14.6% |
| Operating margin | 30.4% | 26.5% |
| Growth | ||
| Revenue growth (YoY) | +33.4% | +17.3% |
| Net profit growth (YoY) | +126.4% | +39.1% |
| Revenue CAGR (multi-year) | +7.2% | +17.7% |
| Financial health | ||
| Debt to equity | 0.41 | 0.31 |
| Momentum | ||
| 1-month return | +17.7% | +11.3% |
| 1-year return | +146.6% | +11.4% |
| 3-year CAGR | +86.6% | +12.9% |
| 5-year CAGR | +37.7% | — |
| Distance from 52W high | -1.2% | -1.1% |
| Technicals | ||
| RSI (14) | 81 | 84 |
| Price vs 200-day avg | +60.7% | +13.3% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Laurus Labs | Mankind Pharma |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 8/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Laurus Labs or Mankind Pharma?
Laurus Labs has a market cap of ₹1,30,969 Cr and Mankind Pharma has a market cap of ₹1,09,032 Cr as of 13 Nov 2026.
Which has a lower P/E, Laurus Labs or Mankind Pharma?
Mankind Pharma has the lower P/E: Laurus Labs trades at 97.7 and Mankind Pharma at 48.5.
Which gave better returns in the last year, Laurus Labs or Mankind Pharma?
Laurus Labs did better: Laurus Labs returned +146.6% and Mankind Pharma returned +11.4% over one year.
What is the difference between Laurus Labs and Mankind Pharma?
Both are NSE-listed companies in Healthcare. Laurus Labs is about 1.2 times the size of Mankind Pharma by market cap. In the latest financial year Laurus Labs reported revenue of ₹6,813 Cr and Mankind Pharma ₹14,278 Cr. Operating margin is 30.4% for Laurus Labs and 26.5% for Mankind Pharma. Debt to equity is 0.41 for Laurus Labs and 0.31 for Mankind Pharma.
Which is better, Laurus Labs or Mankind Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Laurus Labs leads on 10 and Mankind Pharma on 6. Laurus Labs is ahead on profitability, growth, momentum and technicals. Mankind Pharma is ahead on size, valuation and financial health. On StoxGud's rules-based checklist Laurus Labs scores 8/10 and Mankind Pharma scores 7/10. This is information, not advice: consult a SEBI-registered adviser before investing.